CLINICAL REPORTSCetuximab in combination with chemoradiotherapy in the treatment of recurrent and/or metastatic nasopharyngeal carcinomaXu, Tingting*; Ou, Xiaomin*; Shen, Chunying; Hu, ChaosuAuthor Information Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China * Tingting Xu and Xiaomin Ou contributed equally to the writing of this article. Correspondence to Chaosu Hu, MD, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 DongAn Road, Shanghai 200032, China Tel: +86 641 75590; fax: +86 216 417 3612; e-mail: [email protected] Received May 4, 2015 Accepted August 11, 2015 Anti-Cancer Drugs: January 2016 - Volume 27 - Issue 1 - p 66-70 doi: 10.1097/CAD.0000000000000294 Buy Metrics Abstract The aim of the study was to assess the efficacy and toxicity of cetuximab in the combined treatment for patients with recurrent and/or metastatic nasopharyngeal carcinoma (R/M NPC). Between March 2007 and November 2011, a total of 30 R/M NPC patients treated with comprehensive therapy including cetuximab were retrospectively enrolled. Intensity-modulated radiation therapy was delivered in recurrent disease with a median dose of 60 Gy. Chemotherapy regimens included TP/TPF (docetaxel 60–75 mg/m2 d1+DDP 25 mg/m2 d1–3±5-FU 500 mg/m2/day with 120-h infusion), GP (gemcitabine 1.0 g/m2 d1, d8+DDP 25 mg/m2 d1–3), and PC (paclitaxel 60 mg/m2/week d1+carboplatin AUC 2/week d1). Acute and late toxicities were documented by the radiation oncologists. The median age of the patients was 44 years (range 26–62). A total of 21 patients (70%) achieved response (CR+PR). The median survival time, time to progression, and 2-year overall survival were 23.6, 12.2 months, and 53.3%, respectively. Cetuximab appears to be effective and well tolerated when combined with chemoradiation therapy for the treatment of R/M NPC. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.